IL158561A0 - Crystalline form of omerprazole - Google Patents

Crystalline form of omerprazole

Info

Publication number: IL158561A0
Authority: IL; Israel
Prior art keywords: omeprazole; crystalline form; methoxy; disclosed; omerprazole
Prior art date: 2001-04-25

Application number

IL15856102A

Other languages

English (en)

Original Assignee

Lek Tovarna Farmacevtskih

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-04-25

Filing date

2002-04-24

Publication date

2004-05-12

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20432882&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL158561(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2002-04-24 Application filed by Lek Tovarna Farmacevtskih filed Critical Lek Tovarna Farmacevtskih

2004-05-12 Publication of IL158561A0 publication Critical patent/IL158561A0/xx

Links

SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 title abstract 5
229960000381 omeprazole Drugs 0.000 abstract 4
-1 4-methoxy-3,5-dimethyl-2-pyridinyl Chemical group 0.000 abstract 1
208000018522 Gastrointestinal disease Diseases 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
239000000546 pharmaceutical excipient Substances 0.000 abstract 1
239000000126 substance Substances 0.000 abstract 1
239000000758 substrate Substances 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Life Sciences & Earth Sciences (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

IL15856102A 2001-04-25 2002-04-24 Crystalline form of omerprazole IL158561A0 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
SI200100111A SI20875A (sl)	2001-04-25	2001-04-25	Kristalna oblika omeprazola
PCT/IB2002/001350 WO2002085889A1 (en)	2001-04-25	2002-04-24	Crystalline form of omeprazole

Publications (1)

Publication Number	Publication Date
IL158561A0 true IL158561A0 (en)	2004-05-12

Family

ID=20432882

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL15856102A IL158561A0 (en)	2001-04-25	2002-04-24	Crystalline form of omerprazole

Country Status (26)

Country	Link
US (2)	US20040122056A1 (de)
EP (1)	EP1390360B1 (de)
JP (1)	JP4455815B2 (de)
KR (1)	KR20030094358A (de)
CN (1)	CN1531533B (de)
AT (1)	ATE346063T1 (de)
AU (1)	AU2002307892B2 (de)
BG (1)	BG108287A (de)
BR (1)	BR0209103A (de)
CA (1)	CA2445251C (de)
CZ (1)	CZ20032911A3 (de)
DE (1)	DE60216273T2 (de)
HR (1)	HRP20030853B1 (de)
HU (1)	HUP0303928A2 (de)
IL (1)	IL158561A0 (de)
MX (1)	MXPA03009789A (de)
NO (1)	NO20034715L (de)
NZ (1)	NZ528917A (de)
PL (1)	PL366471A1 (de)
RS (1)	RS50880B (de)
RU (1)	RU2286991C2 (de)
SI (2)	SI20875A (de)
SK (1)	SK13192003A3 (de)
UA (1)	UA77671C2 (de)
WO (1)	WO2002085889A1 (de)
ZA (1)	ZA200307988B (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8993599B2 (en)	2003-07-18	2015-03-31	Santarus, Inc.	Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8815916B2 (en)	2004-05-25	2014-08-26	Santarus, Inc.	Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8906940B2 (en)	2004-05-25	2014-12-09	Santarus, Inc.	Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
ES2246149B1 (es) *	2004-07-02	2007-06-01	Esteve Quimica, S.A.	Formas solidas de la sal magnesica de s-omeprazol y procedimientos para su preparacion.
WO2007008588A2 (en) *	2005-07-07	2007-01-18	Dr. Reddy's Laboratories Ltd.	Omeprazole form b
ES2587980T3 (es) *	2006-02-22	2016-10-28	International Institute Of Cancer Immunology, Inc	Péptido WT1 con restricción HLA-A*3303 y composición farmacéutica que lo contiene
WO2008067037A2 (en)	2006-10-05	2008-06-05	Santarus, Inc.	Novel formulations of proton pump inhibitors and methods of using these formulations
EP2086543A2 (de)	2006-10-27	2009-08-12	The Curators of the University of Missouri	Zusammensetzungen mit mindestens einem säurelabilen protonenpumpen-hemmenden mittel, wahlweise anderen pharmazeutisch wirksamen mitteln und anwendungsverfahren dafür
EA200900985A1 (ru)	2007-01-31	2009-12-30	Крка, Товарна Здравил, Д. Д., Ново Место	Способ получения оптически чистого омепразола
RU2339631C1 (ru) *	2007-04-12	2008-11-27	Новосибирский институт органической химии им. Н.Н. Ворожцова СО РАН (НИОХ СО РАН)	Способ получения эзомепразола
WO2010134099A1 (en)	2009-05-21	2010-11-25	Cadila Healthcare Limited	One pot process for preparing omeprazole and related compounds
CN102786513A (zh) *	2011-05-18	2012-11-21	中国医学科学院药物研究所	奥美拉唑晶e型物质及制备方法与在药品和保健品中应用
CN102351846B (zh) *	2011-09-07	2012-08-22	周晓东	一种新的奥美拉唑钠化合物及其药物组合物
KR101459088B1 (ko) *	2012-08-02	2014-12-02	대화제약 주식회사	알-라베프라졸, 이의 금속염의 제조방법
IL312564A (en)	2021-11-05	2024-07-01	Cinclus Pharma Holding Ab Publ	Polymorphs of the hydrochloride salt of linfarezan glurate
JP2025532389A (ja)	2022-10-04	2025-09-29	ザビリュク，アルセニー	大動脈弁の石灰化の抑制
CN119320380B (zh) *	2024-10-14	2025-11-25	山东益康药业股份有限公司	奥美拉唑与2,6-二羟基苯甲酸的共晶物及其用途
CN119320381B (zh) *	2024-10-14	2025-12-12	山东益康药业股份有限公司	奥美拉唑与3,5-二硝基苯甲酸的共晶物及其用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SE7804231L (sv) *	1978-04-14	1979-10-15	Haessle Ab	Magsyrasekretionsmedel
DE69112917T2 (de) *	1990-06-15	1996-05-15	Merck & Co Inc	Kristallisationsverfahren zur Verbesserung der Kristallstruktur und -grösse.
SE510666C2 (sv) *	1996-12-20	1999-06-14	Astra Ab	Nya Kristallmodifikationer
SI20019A (sl) *	1998-07-13	2000-02-29	LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d.	Izboljšan postopek sinteze 5-metoksi -2-/(4-metoksi-3,5-dimetil-2-piridil)metil/ sulfinil-1H-benzimidazola
US6166213A (en) *	1998-08-11	2000-12-26	Merck & Co., Inc.	Omeprazole process and compositions thereof
UA72748C2 (en) *	1998-11-10	2005-04-15	Astrazeneca Ab	A novel crystalline form of omeprazole
AUPQ841800A0 (en) *	2000-06-28	2000-07-20	Biomolecular Research Institute Limited	Truncated egf receptor
US6627646B2 (en) *	2001-07-17	2003-09-30	Sepracor Inc.	Norastemizole polymorphs

2001
- 2001-04-25 SI SI200100111A patent/SI20875A/sl not_active IP Right Cessation
2002
- 2002-04-24 CN CN028089553A patent/CN1531533B/zh not_active Expired - Lifetime
- 2002-04-24 SK SK1319-2003A patent/SK13192003A3/sk unknown
- 2002-04-24 KR KR10-2003-7013767A patent/KR20030094358A/ko not_active Ceased
- 2002-04-24 DE DE60216273T patent/DE60216273T2/de not_active Expired - Lifetime
- 2002-04-24 PL PL02366471A patent/PL366471A1/xx not_active Application Discontinuation
- 2002-04-24 MX MXPA03009789A patent/MXPA03009789A/es active IP Right Grant
- 2002-04-24 WO PCT/IB2002/001350 patent/WO2002085889A1/en not_active Ceased
- 2002-04-24 CA CA2445251A patent/CA2445251C/en not_active Expired - Lifetime
- 2002-04-24 RS YUP-840/03A patent/RS50880B/sr unknown
- 2002-04-24 AT AT02764081T patent/ATE346063T1/de active
- 2002-04-24 SI SI200230491T patent/SI1390360T1/sl unknown
- 2002-04-24 JP JP2002583416A patent/JP4455815B2/ja not_active Expired - Lifetime
- 2002-04-24 AU AU2002307892A patent/AU2002307892B2/en not_active Expired
- 2002-04-24 RU RU2003133213/04A patent/RU2286991C2/ru active
- 2002-04-24 IL IL15856102A patent/IL158561A0/xx unknown
- 2002-04-24 US US10/475,239 patent/US20040122056A1/en not_active Abandoned
- 2002-04-24 CZ CZ20032911A patent/CZ20032911A3/cs unknown
- 2002-04-24 NZ NZ528917A patent/NZ528917A/en unknown
- 2002-04-24 UA UA2003109492A patent/UA77671C2/uk unknown
- 2002-04-24 HR HR20030853A patent/HRP20030853B1/xx not_active IP Right Cessation
- 2002-04-24 EP EP02764081A patent/EP1390360B1/de not_active Expired - Lifetime
- 2002-04-24 HU HU0303928A patent/HUP0303928A2/hu unknown
- 2002-04-24 BR BR0209103-8A patent/BR0209103A/pt not_active Application Discontinuation
2003
- 2003-10-14 ZA ZA200307988A patent/ZA200307988B/xx unknown
- 2003-10-21 NO NO20034715A patent/NO20034715L/no not_active Application Discontinuation
- 2003-10-24 BG BG108287A patent/BG108287A/bg unknown
2005
- 2005-10-12 US US11/248,461 patent/US7553856B2/en not_active Expired - Lifetime

Also Published As

Publication number	Publication date
CZ20032911A3 (en)	2004-06-16
JP4455815B2 (ja)	2010-04-21
EP1390360B1 (de)	2006-11-22
ZA200307988B (en)	2004-10-14
NO20034715L (no)	2003-12-10
SI1390360T1 (sl)	2007-04-30
CA2445251C (en)	2011-01-04
JP2004526786A (ja)	2004-09-02
RS50880B (sr)	2010-08-31
YU84003A (sh)	2006-08-17
HRP20030853A2 (en)	2005-08-31
KR20030094358A (ko)	2003-12-11
US20040122056A1 (en)	2004-06-24
UA77671C2 (en)	2007-01-15
AU2002307892B2 (en)	2008-04-17
HUP0303928A2 (hu)	2004-03-01
DE60216273D1 (de)	2007-01-04
US20060079560A1 (en)	2006-04-13
MXPA03009789A (es)	2005-03-07
NZ528917A (en)	2006-02-24
CN1531533B (zh)	2012-07-18
BG108287A (bg)	2005-04-30
RU2286991C2 (ru)	2006-11-10
PL366471A1 (en)	2005-02-07
SI20875A (sl)	2002-10-31
CN1531533A (zh)	2004-09-22
BR0209103A (pt)	2004-07-13
RU2003133213A (ru)	2005-05-10
US7553856B2 (en)	2009-06-30
WO2002085889A1 (en)	2002-10-31
EP1390360A1 (de)	2004-02-25
DE60216273T2 (de)	2007-05-31
NO20034715D0 (no)	2003-10-21
HRP20030853B1 (en)	2011-11-30
ATE346063T1 (de)	2006-12-15
SK13192003A3 (sk)	2004-03-02
CA2445251A1 (en)	2002-10-31

Publication	Publication Date	Title
ZA200307988B (en)	2004-10-14	Crystalline form of omerprazole.
WO1999008500A3 (en)	1999-07-29	New crystalline form of omeprazole
MY127871A (en)	2006-12-29	Omeprazole sodium salt
CA2357744A1 (en)	2000-08-03	Potassium salt of (s)-omeprazole
WO1998054171A8 (en)	1999-12-23	Novel form of s-omeprazole
AR010361A1 (es)	2000-06-07	"S-OMEPRAZOL [ENANTIoMERO S DE 5-METOXI-2-[[(4--METOXI-3,5-DIMETIL-2-PIRIDINIL)-METIL]SULFINIL]-1H-BENCIMIDAZOL], EN UNA FORMA NEUTRA NO SALINA, PROCESO PARA SU PREPARACION, COMPOSICION FARMACEUTICA, Y SU USO PARA LA MANUFACTURA DE MEDICAMENTOS"
MY111737A (en)	2000-12-30	Use of omeprazole as an antimicrobial agent.
JP2002535401A5 (de)	2007-01-25
MY118199A (en)	2004-09-30	Process for preparing omeprazole
JP2007504223A5 (de)	2007-09-27
SE0302382D0 (sv)	2003-09-04	New salts II
JP2007504222A5 (de)	2007-09-27
MY118724A (en)	2005-01-31	New crystalline form of omeprazole
YU32301A (sh)	2005-07-19	Novi kristalni oblik omeprazola
US20050154026A1 (en)	2005-07-14	Use of proton pump inhibitors for the treatment of noncardiac chest pain
CA2478958A1 (en)	2003-09-18	Use of proton pump inhibitors for the treatment of airway disorders